Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Anderson LD Jr"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19.
    Autorzy:
    Zheng R; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Mieth K; Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Bennett C; Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Miller C; Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Anderson LD Jr; Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Chen M; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Cao J; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Jul 13; Vol. 15 (14). Date of Electronic Publication: 2023 Jul 13.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.
    Autorzy:
    Hoff FW; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Goksu SY; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Premnath N; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Patel PA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Ikpefan R; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Kaur G; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Vusirikala M; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Bat T; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Chen W; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
    Geethakumari PR; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Anderson LD Jr; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Collins RH; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Weinberg OK; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
    Muthukumar A; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
    Chung SS; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
    Madanat YF; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. .
    Pokaż więcej
    Źródło:
    Acta medica academica [Acta Med Acad] 2023 Apr; Vol. 52 (1), pp. 30-36.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    COVID-19*/prevention & control
    Hematologic Neoplasms*
    Humans ; COVID-19 Vaccines ; Immunoglobulin G ; SARS-CoV-2 ; Antibody Formation ; Vaccination
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Preface of the Special Issue "COVID-19 Infection and Hematological Malignancies".
    Autorzy:
    Chen M; Department of Pathology and Laboratory Medicine, Hematopathology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA.
    Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Sep 16; Vol. 14 (18). Date of Electronic Publication: 2022 Sep 16.
    Typ publikacji:
    Editorial
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
    Autorzy:
    Richardson PG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
    Schjesvold F; Oslo Myeloma Center at Oslo University Hospital, KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
    Anderson LD Jr; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
    White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
    Rodriguez-Otero P; Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
    Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    Engelhardt M; Universitätsklinikum Freiburg, Freiburg, Germany.
    Jenner M; Southampton General Hospital, Southampton, UK.
    Corso A; Policlinico San Matteo Universita Di Pavia, Pavia, Italy.
    Dürig J; University Hospital Essen, Essen, Germany.
    Pavic M; Centre Hospitalier Universitaire De Sherbrooke (CHUS), Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, QC, Canada.
    Salomo M; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
    Beksac M; Ankara University, Ankara, Turkey.
    Oriol A; Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
    Lindsay J; East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
    Liberati AM; University of Perugia, Perugia, Italy.
    Galli M; Ospedale Papa Giovanni XXIII, U.O. di Ematologia, Ispedali Riuniti di Bergamo, Bergamo, Italy.
    Robak P; Medical University of Lodz, Lodz, Poland.
    Larocca A; A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy.
    Yagci M; Gazi University Medical Faculty, Ankara, Turkey.
    Vural F; Ege University, Izmir, Turkey.
    Kanate AS; West Virginia University, Morgantown, West Virginia, USA.
    Jiang R; Bristol Myers Squibb, Princeton, New Jersey, USA.
    Grote L; Bristol Myers Squibb, Princeton, New Jersey, USA.
    Peluso T; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
    Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2022 Jan; Vol. 108 (1), pp. 73-83. Date of Electronic Publication: 2021 Sep 22.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Multiple Myeloma/*drug therapy
    Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Drug Resistance, Neoplasm ; Female ; Humans ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Prognosis ; Recurrence ; Retreatment ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
    Autorzy:
    Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain. .
    Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
    Facon T; CHU Lille Service Des Maladies du Sang, 59000, Lille, France.
    Auner HW; Imperial College London, London, UK.
    Leleu X; Department of Hematology, CHU La Miletrie and Inserm CIC 1402, Poitiers, France.
    Hájek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
    Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece.
    Delimpasi S; General Hospital Evangelismos, Athens, Greece.
    Simonova M; Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine.
    Špička I; Charles University and General Hospital, Prague, Czech Republic.
    Pour L; University Hospital Brno, Brno, Czech Republic.
    Kriachok I; National Cancer Institute, Kiev, Ukraine.
    Pylypenko H; Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
    Doronin V; City Clinical Hospital #40, Moscow, Russian Federation.
    Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine.
    Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK.
    Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
    Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
    Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
    Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK.
    Stevens DA; Norton Cancer Institute, St. Matthews Campus, Louisville, KY, USA.
    Quach H; St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
    Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    Moreau P; Hotel-Dieu, University Hospital, Nantes, France.
    Levy M; Baylor University Medical Center, Dallas, TX, USA.
    Badros AZ; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.
    Anderson LD Jr; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
    Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, USA.
    Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
    Chai Y; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Jeha J; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Arazy M; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Shah J; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Kauffman MG; Karyopharm Therapeutics Inc, Newton, MA, USA.
    Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA.
    Grosicki S; Medical University of Silesia, Katowice, Poland.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 13; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2021 Apr 13.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Bortezomib/*therapeutic use
    Dexamethasone/*therapeutic use
    Hydrazines/*therapeutic use
    Multiple Myeloma/*drug therapy
    Triazoles/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Humans ; Hydrazines/pharmacology ; Male ; Multiple Myeloma/pathology ; Triazoles/pharmacology
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
    Autorzy:
    Chari A; a Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , NY , USA.
    Larson S; b University of California , Los Angeles , CA , USA.
    Holkova B; c Virginia Commonwealth University Medical Center , Richmond , VA , USA.
    Cornell RF; d Vanderbilt-Ingram Cancer Center , Nashville , TN , USA.
    Gasparetto C; e Duke University Medical Center , Durham , NC , USA.
    Karanes C; f City of Hope National Medical Center , Duarte , CA , USA.
    Matous JV; g Colorado Blood Cancer Institute , Denver , CO , USA.
    Niesvizky R; h Weill Cornell Medical College , New York , NY , USA.
    Valent J; i Cleveland Clinic , Taussig Cancer Institute , Cleveland , OH , USA.
    Lunning M; j University of Nebraska Medical Center , Omaha , NE , USA.
    Usmani SZ; k Levine Cancer Institute/Carolinas Healthcare System , Charlotte , NC , USA.
    Anderson LD Jr; l Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas , TX , USA.
    Chang L; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Lee Y; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Pak Y; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Salman Z; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Graef T; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Bilotti E; m Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Chhabra S; n Medical University of South Carolina , Charleston , SC , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Nov; Vol. 59 (11), pp. 2588-2594. Date of Electronic Publication: 2018 Apr 04.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Multiple Myeloma/*drug therapy
    Adenine/analogs & derivatives ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/pharmacokinetics ; Diarrhea/chemically induced ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm ; Fatigue/chemically induced ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Oligopeptides/pharmacokinetics ; Outcome Assessment, Health Care/statistics & numerical data ; Piperidines ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Pyrazoles/pharmacokinetics ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies